UK/Japan projects in life sciences to target priority areas

There is around 100m annually in the Sixth Framework Programme earmarked exclusively for small and medium-sized enterprises (SMEs) in the life sciences field. That is 15 per cent of the total amount available. But most of it has yet to be allocated. Why are biopharmaceutical SMEs not applying and how can they get access to this money?The Emerging Biopharmaceutical Enterprises (EBE) group teamed up with representatives of the European Commission for the 'Life Sciences, Genomics and Biotechnology for Health' Thematic Priority to help companies understand how they can benefit from the Programme and give them an opportunity to add their ideas to it. Attendees came from 60 biopharmaceutical companies, and the programme was structured to allow companies to ask questions, but also put forward ideas to be included in upcoming Calls for the Sixth Framework Programme, as well as suggestions for improving the Seventh Framework Programme to improve industry participation. The event also gave them the chance to ask the Commission representatives specific questions on the administrative aspects of the Programme. The event was organised in conjunction with the Scientific Officers responsible for the different areas in the Programme; and the external experts who advise the Commission on the content of the future calls and the overall strategy for priority areas and activities of research were also invited. This meeting was designed to be as relaxed and open as possible and put the companies directly in contact with the people who implement the Framework Programme. The input from this session based on the feedback of the attendees has been formally forwarded to the Commission and the Thematic Priority Advisory Group.This paper discusses the aims and focus of the Sixth Framework Programme. It provides an overview of the discussion between the EBE and the representatives from the European Commission for the 'Life Sciences, Genomics and Biotechnology for Health' Thematic Priority and summarises the key problems and solutions arising therein.

Download Full-text

Priority area “Life sciences, new technologies of prevention and common diseases treatment”: financing and impact analysis

Science, technologies, innovation ◽

10.35668/2520-6524-2020-4-04 ◽

2020 ◽

pp. 34-42

Author(s):

A. B. Osadcha ◽

T. V. Gavrys

Keyword(s):

Structural Changes ◽

Impact Analysis ◽

Agricultural Sector ◽

New Technologies ◽

Technology Development ◽

Life Sciences ◽

Priority Area ◽

Priority Areas ◽

Technical Developments ◽

Common Diseases

In core foundation of the most important priority area of Ukraine “Life sciences, new technologies of prevention and common diseases treatment” are the current problems of modern Ukrainian society, labor productivity in all economy sectors. Rational distribution of funds and a high level of implementation of scientific (scientific and technical) outputs are the driving force of progressive technological structural changes in the economy and an important factor in ensuring the competitiveness of the national economy. The article presents the results of the author’s research on the state of implementation of one of the six priority areas defined by the Law of Ukraine “About Priority Areas of Science and Technology Development” for the period up to 2020, and 12 priority thematic areas of research, scientific and technical developments specified priority and approved by the Resolution of the Cabinet of Ministers of Ukraine from 07.09.2011 No. 942 for the period up to 2020 (as amended in accordance with the resolution of the Cabinet of Ministers of Ukraine from 23.08.2016 No. 556, which supplemented priority thematic areas list with new areas aimed at ensuring national security, increasing the state’s defense capabilities, protecting the civilian population, medicine, the agricultural sector, as well as clarifying the wording of a number of priority thematic areas).

Download Full-text